Latest Safety News

Tasmea Limited has launched a $43 million institutional placement to strengthen its balance sheet for future acquisitions, following a robust FY25 with significant profit growth and margin expansion. The company’s FY26 guidance signals continued momentum driven by organic growth and strategic acquisitions.

Lakes Blue Energy reports promising natural gas indications at its Wombat-5 well, with increasing concentrations of hydrocarbons detected as drilling progresses into the Strzelecki Formation.

Wagners Holding Company Limited has launched a A$30 million institutional placement to reduce debt and accelerate growth in its core Construction Materials and Composite Fibre Technologies businesses following a robust FY25 performance.

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

Orthocell Limited reports an 81.1% overall treatment success rate from its Remplir Real World Evidence study, reinforcing the product’s safety and efficacy as it expands sales in the US and prepares regulatory submissions for the EU and UK.

Finder Energy is fast-tracking its Kuda Tasi and Jahal development with advanced engineering and critical FPSO evaluations, aiming for a Final Investment Decision in 2026. This acceleration seeks to reduce risks and optimize costs ahead of production.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

PYC Therapeutics has completed dosing in its Phase 1 study of PYC-001 for Autosomal Dominant Optic Atrophy, showing strong safety and early signs of improved vision. The company plans to launch a global Phase 1/2 trial later this year.

Botanix Pharmaceuticals’ ECCLOCK® gel, a treatment for excessive sweating, has secured regulatory approval in South Korea, paving the way for a commercial launch in early 2026.

Orica Limited reports robust earnings growth across all segments for FY2025, underpinned by successful gas supply deals, digital expansion, and progress in hydrogen funding despite ongoing litigation costs.

Haranga Resources has successfully commissioned the water treatment plant at its Lincoln Gold Project and begun dewatering, paving the way for its maiden underground drilling program and a JORC resource update by year-end.

Amplia Therapeutics has commenced dosing the first patient in its new pancreatic cancer trial combining narmafotinib with FOLFIRINOX chemotherapy, marking a key milestone in its drug development journey.